Addressing Overdose Risk Among Recently Incarcerated People Living With HIV/AIDS
NCT ID: NCT03569592
Last Updated: 2020-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2018-01-22
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research has the following aims:
* Aim 1: Evaluate a pilot program to provide HIV+ inmates with 1:1 overdose prevention training while incarcerated;
* Aim 2: Identify the criminal justice, health, and HIV-related factors associated with overdose risk; and
* Aim 3: Describe the overdose risk experiences of HIV+ former inmates who use opioids after release.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relapse Prevention to Reduce HIV Among Women Prisoners
NCT00763958
A Setting Focus Overdose Prevention Intervention
NCT05320835
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
NCT00142935
Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance
NCT00622596
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
NCT03135886
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study, incarcerated PLWHA in the Philadelphia Department of Prisons will be offered overdose training while incarcerated and naloxone (Narcan) at release. Study participants will be given a pre-test on overdose knowledge and attitudes and receive the overdose prevention intervention. Those who are still incarcerated one month later will receive a post-test on overdose knowledge and attitudes. Approximately one month after study participants are released from jail, they will be given a one-month follow-up survey that assesses: overdose knowledge and attitudes (post-test 2), information on personal or witnessed overdoses since release, health and post-incarceration related information, and characteristics of drug use since release. Approximately 20 study participants will participate in a semi-structured interview 4-6 weeks after their release on their experiences with the overdose prevention intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Overdose Prevention Intervention
The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
Overdose Prevention Intervention
Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Overdose Prevention Intervention
Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 and over
* Speaks English
* plans to live in Philadelphia area after release
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Drexel University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Drexel University
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1704005362
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.